The past 50 years have seen a growing ageing population with an increasing prevalence of type 2 diabetes mellitus (T2DM); now, nearly half of all individuals with diabetes mellitus are older adults (aged ≥65 years). Older adults with T2DM present particularly difficult challenges. For example, the accentuated heterogeneity of these patients, the potential presence of multiple comorbidities, the increased susceptibility to hypoglycaemia, the increased dependence on care and the effect of frailty all add to the complexity of managing diabetes mellitus in this age group. In this Review, we offer an update on the key pathophysiological mechanisms associated with T2DM in older people. We then evaluate new evidence relating particularly to the effects of frailty and sarcopenia, the clinical difficulties of age-associated comorbidities, and the implications for existing guidelines and therapeutic options. Our conclusions will focus on the effect of T2DM on an ageing society.
Older adults (≥65 years of age) with type 2 diabetes mellitus (T2DM) account for nearly half of all individuals with diabetes mellitus.
T2DM in older adults is highly heterogeneous but is generally associated with various degrees of underlying insulin resistance, excess adiposity, β-cell dysfunction and sarcopenia.
The management of T2DM in older adults is complicated by the frequent occurrence of multimorbidity, necessitating highly individualized approaches.
The presence of frailty, cognitive decline and functional impairments in older adults with T2DM highlights the importance of liaison with carers and social support.
Targets for glycaemic control in older adults with T2DM are often less stringent than in younger adults to avoid hypoglycaemia and minimize unbeneficial interventions.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Khan, M. A. B. et al. Epidemiology of type 2 diabetes — global burden of disease and forecasted trends. J. Epidemiol. Glob. Health 10, 107–111 (2020).
NHS Digital. National Diabetes Audit Report 1: Care Processes and Treatment Targets 2017-18 https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2017-18-short-report (2018).
Sinclair, A., Dunning, T. & Rodriguez-Manas, L. Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol. 3, 275–285 (2015). An excellent synopsis of key clinical issues and unmet needs facing the management of T2DM in older adults.
International Diabetes Federation. IDF Diabetes Atlas 8th Edn. https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf (2017).
Salomon, J. A. et al. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet 380, 2144–2162 (2012).
Dunning, T., Sinclair, A. & Colagiuri, S. New IDF Guideline for managing type 2 diabetes in older people. Diabetes Res. Clin. Pract. 103, 538–540 (2014).
NCD Risk Factor Collaboration (NCD-RisC).Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513–1530 (2016).
Cho, N. H. et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 138, 271–81 (2018).
Center for Disease Control. National Diabetes Statistics Report https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html (2020).
American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes–2018. Diabetes Care 41 (Suppl. 1), S55–S64 (2018).
Leung, E., Wongrakpanich, S. & Munshi, M. N. Diabetes management in the elderly. Diabetes Spectr. 31, 245–53 (2018).
Miller, R. G., Secrest, A. M., Sharma, R. K., Songer, T. J. & Orchard, T. J. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 61, 2987–2992 (2012).
Kirkman, M. S. et al. Diabetes in older adults: a consensus report. J. Am. Geriatr. Soc. 60, 2342–2356 (2012).
American Diabetes Association. Standards of Medical Care in Diabetes — 2021; Chapter 12, older adults. Diabetes Care 44 (Suppl 1), S168–S179 (2021).
DeFronzo, R. A. Pathogenesis of type 2 diabetes mellitus. Med. Clin. North. Am. 88, 787–835 (2004).
Lee, P. G. & Halter, J. B. The pathophysiology of hyperglycemia in older adults: clinical considerations. Diabetes Care 40, 444–452 (2017).
Chia, C. W., Egan, J. M. & Ferrucci, L. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk. Circ. Res. 123, 886–904 (2018).
Chang, A. M., Smith, M. J., Galecki, A. T., Bloem, C. J. & Halter, J. B. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J. Clin. Endocrinol. Metab. 91, 3303–3309 (2006).
Li, N. et al. Aging and stress induced beta cell senescence and its implication in diabetes development. Aging 11, 9947–9959 (2019).
Ferrannini, E. et al. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 45, 947–953 (1996).
Karakelides, H., Irving, B. A., Short, K. R., O’Brien, P. & Nair, K. S. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes 59, 89–97 (2010).
Amati, F. et al. Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care 32, 1547–1549 (2009).
Shou, J., Chen, P. J. & Xiao, W. H. Mechanism of increased risk of insulin resistance in aging skeletal muscle. Diabetol. Metab. Syndr. 12, 14 (2020).
Buffa, R., Floris, G. U., Putzu, P. F. & Marini, E. Body composition variations in ageing. Coll. Antropol. 35, 259–265 (2011).
Kyrou, I. & Tsigos, C. Obesity in the elderly diabetic patient: is weight loss beneficial? Diabetes Care 32 (Suppl. 2), 403–409 (2009).
Al-Sofiani, M. E., Ganji, S. S. & Kalyani, R. R. Body composition changes in diabetes and aging. J. Diabetes Complications 33, 451–459 (2019).
Tsai, A. C. & Lee, S. H. Determinants of new-onset diabetes in older adults-Results of a national cohort study. Clin. Nutr. 34, 937–942 (2015).
Conn, V. S., Minor, M. A., Burks, K. J., Rantz, M. J. & Pomeroy, S. H. Integrative review of physical activity intervention research with aging adults. J. Am. Geriatr. Soc. 51, 1159–1168 (2003).
Petersen, K. F. & Shulman, G. I. Etiology of insulin resistance. Am. J. Med. 119 (Suppl. 1), S10–S16 (2006).
Mancuso, P. & Bouchard, B. The impact of aging on adipose function and adipokine synthesis. Front. Endocrinol. 10, 137 (2019).
Martyniak, K. & Masternak, M. M. Changes in adipose tissue cellular composition during obesity and aging as a cause of metabolic dysregulation. Exp. Gerontol. 94, 59–63 (2017).
Petersen, K. F. et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140–1142 (2003).
Groen, B. B. et al. Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes. J. Appl. Physiol. 116, 998–1005 (2014).
Ahima, R. S. Connecting obesity, aging and diabetes. Nat. Med. 15, 996–997 (2009).
Crescioli, C. Targeting age-dependent functional and metabolic decline of human skeletal muscle: the geroprotective role of exercise, myokine IL-6, and vitamin D. Int. J. Mol. Sci. 21, 1010 (2020).
Kalinkovich, A. & Livshits, G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res. Rev. 35, 200–21 (2017).
Jiao, J. & Demontis, F. Skeletal muscle autophagy and its role in sarcopenia and organismal aging. Curr. Opin. Pharmacol. 34, 1–6 (2017).
Wang, J. et al. Association between telomere length and diabetes mellitus: A meta-analysis. J. Int. Med. Res. 44, 1156–73 (2016).
Burton, D. G. A. & Faragher, R. G. A. Obesity and type-2 diabetes as inducers of premature cellular senescence and ageing. Biogerontology 19, 447–59 (2018).
Kyrou, I. & Tsigos, C. Stress hormones: physiological stress and regulation of metabolism. Curr. Opin. Pharmacol. 9, 787–793 (2009).
Selvin, E., Coresh, J. & Brancati, F. L. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care 29, 2415–2419 (2006).
Dunning, T. Care of older people with diabetes. Nurs. Stand. 32, 50–63 (2017).
Munshi, M. N. et al. Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes Endocrinol. 8, 855–867 (2020). A highly informative insight into key research questions and research needs relating to T2DM in older adults.
Godino, J. G. et al. Diabetes, hyperglycemia, and the burden of functional disability among older adults in a community-based study. J. Diabetes 9, 76–84 (2017).
Cesari, M. et al. Frailty: an emerging public health priority. J. Am. Med. Dir. Assoc. 17, 188–192 (2016).
Fried, L. P. et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146–M156 (2001).
Rockwood, K. & Mitnitski, A. Frailty in relation to the accumulation of deficits. J. Gerontol. A Biol. Sci. Med. Sci. 62, 722–727 (2007).
Collard, R. M., Boter, H., Schoevers, R. A., Oude & Voshaar, R. C. Prevalence of frailty in community-dwelling older persons: a systematic review. J. Am. Geriatr. Soc. 60, 1487–1492 (2012).
Sinclair, A. & Morley, J. Frailty and diabetes. Lancet 382, 1386–1387 (2013). A comprehensive assessment of the implications of frailty for the management of diabetes mellitus.
Abdelhafiz, A. H. & Sinclair, A. J. Low HbA1c and increased mortality risk-is frailty a confounding factor? Aging Dis. 6, 262–270 (2015).
Castrejon-Perez, R. C., Aguilar-Salinas, C. A., Gutierrez-Robledo, L. M., Cesari, M. & Perez-Zepeda, M. U. Frailty, diabetes, and the convergence of chronic disease in an age-related condition: a population-based nationwide cross-sectional analysis of the Mexican nutrition and health survey. Aging Clin. Exp. Res. 30, 935–941 (2018).
Hsu, A., Gan, S., Cenzer-Stijacic, I. & Lee, S. J. Glycemic control and functional decline in nursing home residents with diabetes. JAMA Intern. Med. 177, 130–132 (2017).
Yau, C. K. et al. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J. Am. Geriatr. Soc. 60, 1215–1221 (2012).
Zaslavsky, O., Walker, R. L., Crane, P. K., Gray, S. L. & Larson, E. B. Glucose levels and risk of frailty. J. Gerontol. A Biol. Sci. Med. Sci. 71, 1223–1229 (2016).
Rodriguez-Manas, L. et al. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. J. Cachexia Sarcopenia Muscle 10, 721–733 (2019).
Strain, W. D., Agarwal, A. S. & Paldanius, P. M. Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study. Aging 9, 769–777 (2017).
Kalyani, R. R., Saudek, C. D., Brancati, F. L. & Selvin, E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Diabetes Care 33, 1055–1060 (2010).
Rodriguez-Poncelas, A. et al. Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older. Int. J. Clin. Pract. 72, e13075 (2018).
Huang, E. S., Zhang, Q., Gandra, N., Chin, M. H. & Meltzer, D. O. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann. Intern. Med. 149, 11–19 (2008).
Cruz-Jentoft, A. J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48, 601 (2019).
Vellas, B. et al. Sarcopenia trials in specific diseases: report by the International Conference on frailty and sarcopenia research task force. J. Frailty Aging 5, 194–200 (2016).
Jang, H. C. Sarcopenia, frailty, and diabetes in older adults. Diabetes Metab. J. 40, 182–189 (2016).
Zhang, X. et al. Falls among older adults with sarcopenia dwelling in nursing home or community: a meta-analysis. Clin. Nutr. 39, 33–39 (2020).
Zhang, X. et al. Sarcopenia as a predictor of all-cause mortality among older nursing home residents: a systematic review and meta-analysis. BMJ Open 8, e021252 (2018).
Mesinovic, J., Zengin, A., De Courten, B., Ebeling, P. R. & Scott, D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab. Syndr. Obes. 12, 1057–1072 (2019). A useful perspective on the complexities of the relationship between sarcopenia and T2DM.
Marcell, T. J. Sarcopenia: causes, consequences, and preventions. J. Gerontol. A Biol. Sci. Med. Sci. 58, M911–M916 (2003).
Hughes, V. A., Frontera, W. R., Roubenoff, R., Evans, W. J. & Singh, M. A. Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. Am. J. Clin. Nutr. 76, 473–481 (2002).
Kim, K. S. et al. Type 2 diabetes is associated with low muscle mass in older adults. Geriatr. Gerontol. Int. 14, 115–121 (2014).
Leenders, M. et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J. Am. Med. Dir. Assoc. 14, 585–592 (2013).
Park, S. W. et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 32, 1993–1997 (2009).
Park, S. W. et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 30, 1507–1512 (2007).
Bianchi, L. & Volpato, S. Muscle dysfunction in type 2 diabetes: a major threat to patient’s mobility and independence. Acta Diabetol. 53, 879–889 (2016).
Kim, T. N. et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 33, 1497–1499 (2010).
Anbalagan, V. P. et al. The prevalence of presarcopenia in Asian Indian individuals with and without type 2 diabetes. Diabetes Technol. Ther. 15, 768–775 (2013).
Scott, D., de Courten, B. & Ebeling, P. R. Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia’s ageing population? Med. J. Aust. 207, 89 (2017).
Cleasby, M. E., Jamieson, P. M. & Atherton, P. J. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J. Endocrinol. 229, R67–R81 (2016).
Yoon, J. W. et al. Hyperglycemia is associated with impaired muscle quality in older men with diabetes: the Korean Longitudinal Study on Health and Aging. Diabetes Metab. J. 40, 140–146 (2016).
Graveling, A. J. & Frier, B. M. Hypoglycaemia: an overview. Prim. Care Diabetes 3, 131–139 (2009).
Zammitt, N. N. & Frier, B. M. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28, 2948–2961 (2005).
Henderson, J. N., Allen, K. V., Deary, I. J. & Frier, B. M. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet. Med. 20, 1016–1021 (2003).
No Authors Listed. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).
Shorr, R. I., Ray, W. A., Daugherty, J. R. & Griffin, M. R. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch. Intern. Med. 157, 1681–1686 (1997).
Davis, T. M. et al. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle Diabetes Study. J. Clin. Endocrinol. Metab. 95, 2240–2247 (2010).
Matyka, K. et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 20, 135–141 (1997).
Meneilly, G. S., Cheung, E. & Tuokko, H. Altered responses to hypoglycemia of healthy elderly people. J. Clin. Endocrinol. Metab. 78, 1341–1348 (1994).
Holstein, A., Plaschke, A. & Egberts, E. H. Clinical characterisation of severe hypoglycaemia-a prospective population-based study. Exp. Clin. Endocrinol. Diabetes 111, 364–369 (2003).
Hope, S. V., Taylor, P. J., Shields, B. M., Hattersley, A. T. & Hamilton, W. Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Prim. Care Diabetes 12, 139–146 (2018). This paper draws attention to the problem of missed hypoglycaemia in older patients with insulin-treated diabetes mellitus.
Bonds, D. E. et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340, b4909 (2010).
Zoungas, S. et al. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363, 1410–1418 (2010).
Davis, S. N. et al. Effects of severe hypoglycemia on cardiovascular outcomes and death in the Veterans Affairs Diabetes Trial. Diabetes Care 42, 157–163 (2019).
Miller, M. E. et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care 37, 634–643 (2014).
Lee, A. K. et al. Severe hypoglycemia and risk of falls in type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 43, 2060–2065 (2020).
Munshi, M. et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 29, 1794–1799 (2006).
Rawlings, A. M. et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann. Intern. Med. 161, 785–793 (2014).
Luchsinger, J. A., Tang, M. X., Stern, Y., Shea, S. & Mayeux, R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 154, 635–641 (2001).
Ott, A. et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53, 1937–1942 (1999).
Peila, R., Rodriguez, B. L., Launer, L. J. & Honolulu-Asia Aging, S. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51, 1256–1262 (2002).
Mansur, R. B. et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: a meta-analysis. Ann. Clin. Psychiatry 30, 38–50 (2018). A meta-analysis that highlights the range of determinants and presentations of cognitive decline in individuals with T2DM.
Cholerton, B., Baker, L. D., Montine, T. J. & Craft, S. Type 2 diabetes, cognition, and dementia in older adults: toward a precision health approach. Diabetes Spectr. 29, 210–219 (2016).
Janssen, J. et al. HbA1c, insulin resistance, and beta-cell function in relation to cognitive function in type 2 diabetes: the CAROLINA cognition substudy. Diabetes Care 42, e1–e3 (2019).
Zhong, Y. et al. The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients. Biomed. Env. Sci. 25, 1–7 (2012).
Huang, L., Yang, L., Shen, X. & Yan, S. Relationship between glycated hemoglobin A1c and cognitive function in nondemented elderly patients with type 2 diabetes. Metab. Brain Dis. 31, 347–353 (2016).
Lacy, M. E. et al. Long-term glycemic control and dementia risk in type 1 diabetes. Diabetes Care 41, 2339–2345 (2018).
Tuligenga, R. H. et al. Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol. 2, 228–235 (2014).
Umegaki, H. et al. The associations among insulin resistance, hyperglycemia, physical performance, diabetes mellitus, and cognitive function in relatively healthy older adults with subtle cognitive dysfunction. Front. Aging Neurosci. 9, 72 (2017).
Kong, S. H., Park, Y. J., Lee, J. Y., Cho, N. H. & Moon, M. K. Insulin resistance is associated with cognitive decline among older Koreans with normal baseline cognitive function: a prospective community-based cohort study. Sci. Rep. 8, 650 (2018).
van Gemert, T. et al. Cognitive function is impaired in patients with recently diagnosed type 2 diabetes, but not type 1 diabetes. J. Diabetes Res. 2018, 1470476 (2018).
Ben Assayag, E. et al. Type 2 diabetes mellitus and impaired renal function are associated with brain alterations and poststroke cognitive decline. Stroke 48, 2368–2374 (2017).
Kawamura, T. et al. Effect of renal impairment on cognitive function during a 3-year follow up in elderly patients with type 2 diabetes: association with microinflammation. J. Diabetes Investig. 5, 597–605 (2014).
Talfournier, J. et al. Relationship between blood pressure, cognitive function and education level in elderly patients with diabetes: a preliminary study. Diabetes Metab. 39, 418–423 (2013).
Danna, S. M., Graham, E., Burns, R. J., Deschenes, S. S. & Schmitz, N. Association between depressive symptoms and cognitive function in persons with diabetes mellitus: a systematic review. PLoS One 11, e0160809 (2016).
Weinstein, G., Elran Barak, R., Schnaider Beeri, M. & Ravona-Springer, R. Personality traits and cognitive function in old-adults with type-2 diabetes. Aging Ment. Health 23, 1317–1325 (2019).
Blackwood, J. Cognitive function and falls in older adults with type 2 diabetes mellitus. J. Geriatr. Phys. Ther. 42, E91–E96 (2019).
Smith, D. et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One 12, e0170651 (2017).
Munshi, M. N. Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care 40, 461–467 (2017).
Zhao, R. R., O’Sullivan, A. J. & Fiatarone Singh, M. A. Exercise or physical activity and cognitive function in adults with type 2 diabetes, insulin resistance or impaired glucose tolerance: a systematic review. Eur. Rev. Aging Phys. Act. 15, 1 (2018).
World Health Organization. Multimorbidity: technical series on safer primary care https://apps.who.int/iris/bitstream/handle/10665/252275/9789241511650-eng.pdf?sequence=1 (2016).
Nunes, B. P., Flores, T. R., Mielke, G. I., Thume, E. & Facchini, L. A. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch. Gerontol. Geriatr. 67, 130–138 (2016).
Cassell, A. et al. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br. J. Gen. Pract. 68, e245–e251 (2018).
Melis, R., Marengoni, A., Angleman, S. & Fratiglioni, L. Incidence and predictors of multimorbidity in the elderly: a population-based longitudinal study. PLoS One 9, e103120 (2014).
Perez Fernandez, M. et al. Comorbidity, frailty, and waitlist mortality among kidney transplant candidates of all ages. Am. J. Nephrol. 49, 103–110 (2019).
Piette, J. D. & Kerr, E. A. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 29, 725–731 (2006).
Eurich, D. T., Majumdar, S. R., Tsuyuki, R. T. & Johnson, J. A. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 27, 1330–1334 (2004).
Kennedy, B. K. et al. Geroscience: linking aging to chronic disease. Cell 159, 709–713 (2014).
Wolff, J. L., Starfield, B. & Anderson, G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch. Intern. Med. 162, 2269–2276 (2002).
Quinones, A. R., Markwardt, S. & Botoseneanu, A. Diabetes-multimorbidity combinations and disability among middle-aged and older adults. J. Gen. Intern. Med. 34, 944–951 (2019).
Laiteerapong, N. et al. Correlates of quality of life in older adults with diabetes: the Diabetes & Aging Study. Diabetes Care 34, 1749–1753 (2011).
Magnan, E. M. et al. The relationship of individual comorbid chronic conditions to diabetes care quality. BMJ Open Diabetes Res. Care 3, e000080 (2015).
Heisler, M. et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? J. Gen. Intern. Med. 18, 893–902 (2003).
Crandall, J. P. et al. The prevention of type 2 diabetes. Nat. Clin. Pract. Endocrinol. Metab. 4, 382–393 (2008).
Pan, X. R. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20, 537–544 (1997).
Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343–1350 (2001).
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
Crandall, J. et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J. Gerontol. A Biol. Sci. Med. Sci. 61, 1075–1081 (2006).
Valabhji, J. et al. Early outcomes from the english national health service diabetes prevention programme. Diabetes Care 43, 152–160 (2020).
Stevens, J. W. et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Res. Clin. Pract. 107, 320–331 (2015).
Strain, W. D. et al. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabet. Med. 35, 838–845 (2018).
Sinclair, A. et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J. Am. Med. Dir. Assoc. 13, 497–502 (2012).
Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669–2701 (2018).
Garber, A. J. et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm — 2019 executive summary. Endocr. Pract. 25, 69–100 (2019).
Sinclair, A. J. et al. An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017. J. Frailty Aging 7, 10–20 (2018).
Khunti, K. & Seidu, S. Therapeutic inertia and the legacy of dysglycemia on the microvascular and macrovascular complications of diabetes. Diabetes Care 42, 349–351 (2019).
Sinclair, A. J., Gadsby, R., Abdelhafiz, A. H. & Kennedy, M. Failing to meet the needs of generations of care home residents with diabetes: a review of the literature and a call for action. Diabet. Med. 35, 1144–1156 (2018).
Strain, W. D., Lukashevich, V., Kothny, W., Hoellinger, M. J. & Paldanius, P. M. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 382, 409–416 (2013).
Yakaryilmaz, F. D. & Ozturk, Z. A. Treatment of type 2 diabetes mellitus in the elderly. World J. Diabetes 8, 278–285 (2017).
Home, P. et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 37, 1499–1508 (2014).
Valdes-Ramos, R., Guadarrama-Lopez, A. L., Martinez-Carrillo, B. E. & Benitez-Arciniega, A. D. Vitamins and type 2 diabetes mellitus. Endocr. Metab. Immune Disord. Drug. Targets 15, 54–63 (2015).
de Rekeneire, N. & Volpato, S. Physical function and disability in older adults with diabetes. Clin. Geriatr. Med. 31, 51–65 (2015).
Lee, J., Kim, D. & Kim, C. Resistance training for glycemic control, muscular strength, and lean body mass in old type 2 diabetic patients: a meta-analysis. Diabetes Ther. 8, 459–473 (2017).
Dixit, S., Maiya, A. & Shastry, B. A. Effect of moderate-intensity aerobic exercise on glycosylated haemoglobin among elderly patients with type 2 diabetes & peripheral neuropathy. Indian J. Med. Res. 145, 129–132 (2017).
Emerenziani, G. P. et al. Effects of aerobic exercise based upon heart rate at aerobic threshold in obese elderly subjects with type 2 diabetes. Int. J. Endocrinol. 2015, 695297 (2015).
Sinclair, A. J., Abdelhafiz, A. H. & Rodriguez-Manas, L. Frailty and sarcopenia - newly emerging and high impact complications of diabetes. J. Diabetes Complications 31, 1465–1473 (2017).
Pan, B. et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Int. J. Behav. Nutr. Phys. Act. 15, 72 (2018).
Villareal, D. T. et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N. Engl. J. Med. 376, 1943–1955 (2017).
Brannick, B. & Dagogo-Jack, S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol. Metab. Clin. North. Am. 47, 33–50 (2018).
Shang, Y. et al. Natural history of prediabetes in older adults from a population-based longitudinal study. J. Intern. Med. 286, 326–340 (2019). A study showing the value of T2DM prevention strategies in older adults.
LeRoith, D. et al. Treatment of diabetes in older adults: an endocrine society* clinical practice guideline. J. Clin. Endocrinol. Metab. 104, 1520–1574 (2019).
Shenoy, P. & Harugeri, A. Elderly patients’ participation in clinical trials. Perspect. Clin. Res. 6, 184–189 (2015).
Tahrani, A. A., Barnett, A. H. & Bailey, C. J. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 12, 566–592 (2016). An overview of pharmacological treatment options for T2DM.
Wang, C. P., Lorenzo, C. & Espinoza, S. E. Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. J. Endocrinol. Diabetes Obes. 2, 1031 (2014).
Sumantri, S., Setiati, S., Purnamasari, D. & Dewiasty, E. Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes. Acta Med. Indones. 46, 183–188 (2014).
Apolzan, J. W. et al. Long-term weight loss with metformin or lifestyle intervention in the diabetes prevention program outcomes study. Ann. Intern. Med. 170, 682–690 (2019).
Porter, K. M. et al. Hyperglycemia and metformin use are associated with B vitamin deficiency and cognitive dysfunction in older adults. J. Clin. Endocrinol. Metab. 104, 4837–4847 (2019).
Schlender, L. et al. Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 17, 227 (2017).
Bailey, C. J. Safety of antidiabetes medications: An update. Clin. Pharmacol. Ther. 98, 185–195 (2015).
Andersen, S. E. & Christensen, M. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br. J. Clin. Pharmacol. 82, 1291–1302 (2016).
Munshi, M. N. et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch. Intern. Med. 171, 362–364 (2011).
Rosenstock, J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322, 1155–1166 (2019).
Barnett, A. et al. Efficacy and safety of linagliptin in elderly patients (>70 years) with type 2 diabetes. Diabetes 61, A260–A261 (2012).
Patel, S. et al. Renal safety of linagliptin in elderly patients with type 2 diabetes mellitus (T2DM): analysis of pooled patient data from 7 phase 3 clinical trials. J. Am. Geriatr. Soc. 62, S182 (2014).
Hartley, P. et al. Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, non-inferiority trial. Drugs Aging 32, 469–476 (2015).
Bethel, M. A. et al. Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Care 40, 494–501 (2017).
Leiter, L. A. et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 38, 1145–1153 (2015).
Rosenstock, J. et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321, 69–79 (2019).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
Monteiro, P. et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. Age Ageing 48, 859–866 (2019).
Custodio, J. S. Jr., Roriz-Filho, J., Cavalcanti, C. A. J., Martins, A. & Salles, J. E. N. Use of SGLT2 inhibitors in older adults: scientific evidence and practical aspects. Drugs Aging 37, 399–409 (2020).
Scheen, A. J. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 16, 556–577 (2020).
Meneilly, G. S. et al. Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: The GetGoal-O randomized trial. Diabetes Care 40, 485–493 (2017).
Pawaskar, M., Li, Q. & Reynolds, M. W. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting. Curr. Med. Res. Opin. 28, 991–997 (2012).
Gilbert, M. P. et al. Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial. Ann. Intern. Med. 170, 423–426 (2019).
Scheen, A. J. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res. Clin. Pract. 143, 88–100 (2018).
Rajagopalan, R., Perez, A., Ye, Z., Khan, M. & Murray, F. T. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging 21, 259–271 (2004).
Graham, D. J. et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411–418 (2010).
Vaccaro, O. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 5, 887–897 (2017).
Hanefeld, M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc. Diabetol. 6, 20 (2007).
Josse, R. G. et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res. Clin. Pract. 59, 37–42 (2003).
S.B. has received research grants from The Binding Site Ltd. and Novo Nordisk, UK, Ltd. as well as speaker fees and honoraria from AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Janssen, Eli Lilly, and Sanofi-Aventis outside of the submitted work. C.J.B. has received personal fees from AstraZeneca, Boehringer Ingelheim, Elcelyx, Lexicon, Poxel, Eli Lilly, Janssen, Merck, Sharpe & Dohme, Novo Nordisk, and Sanofi-Aventis. J.E.B. has received speaker fees from Gilead Biosciences Inc. I.K. has no competing interests to declare.
Peer review information
Nature Reviews Endocrinology thanks L. Rodriguez-Mañas and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literature searches were conducted using Google Scholar, MEDLINE and Embase with the following terms: ‘elderly’, ‘frail’, ‘older people’ and ‘aged’ combined with ‘diabetes’, ‘type 2 diabetes’, ‘prediabetes’ and ‘glucose control’. The selection was made by at least two of the present authors and was limited to English language articles from 2000 to 2020 and relevant references cited in the publications selected. Priority was given to prospective randomized studies and meta-analyses, though these were scarce, and observational and descriptive studies, guidelines, and policy documents were also consulted.
About this article
Cite this article
Bellary, S., Kyrou, I., Brown, J.E. et al. Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol 17, 534–548 (2021). https://doi.org/10.1038/s41574-021-00512-2